ASX Share rice
Mon 17 May 2021 - 03:34:am (Sydney)

SUD Share Price

SUDA PHARMACEUTICALS LTDSUDPharmaceuticals, Biotechnology & Life Sciences

SUD Company Information


Suda Pharmaceuticals Ltd





GIC Industry:


GIC Sub Industry:



55 Howe Street Osborne Park WA Australia 6017


61 8 6142 5555

CEO, MD, CTO & Director:

Dr. Michael Baker


Mr. Stephen John Carter

Exec. Director:

Mr. David Phillips

Company Sec. & CFO:

Mr. Phillip Hains C.A., M.B.A., B Bus, CA, MBA

Project Director & Member of Scientific Advisory Board:

Dr. Richard Franklin


Tony Macintyre

Company Overview:

Suda Pharmaceuticals Ltd engages in the development of drug delivery technology in Australia, India, Europe and Korea. It offers ZolpiMist, an oro-mucosal spray formulation of zolpidem tartrate marketed under the brand name of Ambien or Stilnox, a non-benzodiazepine prescribed for the short-term treatment of insomnia. The company's product pipeline includes Sumatriptan, an oral spray formulation for the treatment of acute migraine; and anagrelide, a platelet lowering agent for use in thrombosis, which is used for the treatment of cancer. Suda Pharmaceuticals Ltd has license and supply agreement with Teva Pharmaceuticals International GmbH and Mitsubishi Tanabe Pharma Singapore for ZolpiMist oral spray; product development, licence, and supply agreement with Cann Pharmaceutical Australia Ltd for the development of novel oral spray of pharmaceutical-grade cannabinoid derivatives for the treatment of drug resistant epilepsy, melanoma, and motion sickness; and feasibility and option agreement with Zelira Therapeutics for the use of cannabinoids for a range of uses, including insomnia, autism, opioid reduction, anxiety, pain, and cancer. The company also has a feasibility study and option agreement with Laboratorios Ordesa, S.L. The company was formerly known as Suda Limited and changed its name to Suda Pharmaceuticals Ltd in November 2017. Suda Pharmaceuticals Ltd was incorporated in 1999 and is headquartered in Osborne Park, Australia.

SUD Share Price Information

Shares Issued:


Market Capitalisation:


Revenue (TTM):


Revenue Per Share (TTM):


Earnings per Share:


Operating Margin (TTM):


Return On Assets (TTM):


Return On Equity (TTM):


Quarterly Revenue Growth (YOY):


Gross Profit(TTM):


Diluted Earnings Per Share (TTM):


SUD CashFlow Statement

CashFlow Date:




Change To Liabilities:


Total Cashflow From Investing Activities:


Net Borrowings:


Net Income:


Total Cash From Operating Activities:




Change To Account Receivables:


Capital Expenditures:


SUD Income Statement

Income Date:


Income Before Tax:


Net Income:


Gross Profit:


Operating Income:


Other Operating Expenses:


Interest Expense:


Income Tax Expense:


Total Revenue:


Cost Of Revenue:


SUD Balance Sheet

Balance Sheet Date:


Intangible Assets:


Total Liabilities:


Total Stockholder Equity:


Other Current Liabilities:


Total Assets:


Common Stock:


Other Current Assets:


Retained Earnings:


Other Liabilities:


Other Assets:




Total Current Liabilities:


Property - Plant & Equipment:


Net Tangible Assets:


Total Current Assets:


Long-Term Debt:


Net Receivables:


Short-Term Investments:




Accounts Payable:


Short-Term Investments:


Non Current Liabilities Total:


SUD Share Price History

SUD News